// App-Quantinova.ai

2231 : IO125 is a potent inducer of tumor immunogenicity

Researchers

Presenter

  • Sanghamitra Mylavarapu

Principal Investigators

  • Shelly Kaushik

  • Yashpal Yadav

  • Monideepa Roy

  • Aniruddha Sengupta

  • Shiladitya Sengupta

Medical Centers

  • Invictus Oncology, New Delhi, India

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Locations

  • United States

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Lewis lung carcinoma

  • Lung Cancer

  • Breast cancer

  • Solid malignancies

  • Melanoma

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Immunoglobulin Kappa Constant

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved